Global Cancer Drugs Market Outlook To 2025: Key Disease Type (Blood Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Kidney Cancer), Treatment Categories (Chemotherapy ((Alkylating Agents, and Antimetabolites), Targeted Therapy (Monoclonal Antibodies and Tyrosine Kinase Inhibitors), Immunotherapy, Hormonal), Distribution Channel (Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy), Regional Segmentation, Competitive Dynamics, M&A Insights, Pricing Analysis (OPP, IPP, RAP), And Segment Forecast

$5,650.00$12,650.00

Clear
  • Report Description
  • Table of Content
  • Highlight
  • Research Methodology
  • Request Free Sample

The global cancer drugs market was valued at $87.6 Billion in 2017 and is forecast to grow at a modest xx.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $135.5 Billion.

 

As per WHO, 8.8 million people worldwide died from cancer in 2015. The most common causes of cancer death are cancers of Lung (1.69 million deaths), Liver (788 000 deaths), Colorectal (774 000 deaths), Stomach (754 000 deaths), Breast (571 000 deaths). Nearly 1 out of every 6 deaths globally. 30-50% of cancer cases can be prevented. It’s causing an annual economic cost of USD 1.16 trillion globally. Cancer-causing infections, such as hepatitis and human papillomavirus (HPV), are responsible for up to 25% of cancer cases in low- and middle-income countries.

 

Cancer arises from the transformation of normal cells into tumor cells in a multistage process that generally progresses from a pre-cancerous lesion to a malignant tumor. This can result in individuals’ genetic factors along with physical carcinogens, chemical carcinogens, and biological carcinogens.

 

Global Cancer Drugs Market Outlook To 2025

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Cancer Drugs”

 

Estimated Average product/ service cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the U.S., the cancer drugs are available at USD xxx- USD xxxx. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.

 

 

 Cancer Drugs Market by “Disease Type”

 

We have segmented the Cancer Drugs market into Blood Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Kidney Cancer.  Lung Cancer is the major cause of death due to cancer followed by Liver and Breast Cancer. We are estimating breast cancer to grow at a CAGR of 25.8% during the forecast period. With an aging population and change in lifestyle, the incidence of cancer is rising steadily.

 

 Cancer Drugs Market by “Treatment Categories”

 

We have segmented the Cancer Drugs market by treatment into Chemotherapy ((Alkylating Agents, and Antimetabolites), Targeted Therapy (Monoclonal Antibodies and Tyrosine Kinase Inhibitors), Immunotherapy and Hormonal. We are observing newer biologic into immunotherapy shaping the Cancer Drugs. Advancing novel therapeutic agents for the treatment of malignancy proving costly and lengthy process. Cost estimates for de novo drug discovery range from $500 million to $2 billion.

 

 Cancer Drugs Market by “Distribution Channel”

 

We have segmented the cancer drugs market based on distribution channel as Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy. Majority of products channelized through hospitals (Particularly Chemo, Surgery and Radiation). However, we are observing the increased role of specialized pharmacy and E-pharmacy in the distribution/ dispensation of treatment drugs. Patient education to increase compliance and Persistency plays a key role in the outcome. Many payors are linking reimbursement to the outcome.

 

 

Regional Segmentation

 

North America accounted for the maximum revenue share of over 70% in 2017 due to increased patient number, lifestyle followed by availability of treatment options, better reimbursement plan, and RND.  Followed by EU- Top 5 countries contribute $X.6 Billion in 2017 and expected to reach $x.5 Billion by 2023.

With changing lifestyle in developing countries and availability of treatment option, we are observing a rise in patient numbers in developing countries. However, these markets represent a minuscule percentage of the overall market.

 

“Competitive Landscape” and “Merger & Acquisition Insights”

 

The key market participants include AstraZeneca, Bristol Myers Squibb, Bayer AG, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Takeda Pharmaceutical, Merck & Co., Genentech Inc., Boehringer Ingelheim, and F. Hoffman-La Roche Ltd. The growing investment in research and development is driving the companies to innovate, stay market relevant and retain their share. Moreover, there are several startup companies working on stem cell and biologic research, and these companies are considered as strategic assets for merger and acquisition. Non-platinum based PARP inhibitors and VEGF inhibitors are changing the treatment paradigm for cancer significantly. We are observing a new drug development for cancer ONX-0801 is in Phase1. Some of the most notable transactions in the recent past include,

  • Novogen Limited, an oncology-focused biotechnology company, becomes Kazia Therapeutics Limited.
  • Tesaro’s acquisition with prospective bidder has diminished in event of news that rival drugs from AstraZeneca and Clovis are just as effective as Tesaro’s niraparib.

 

Market Segmentation

 

 Cancer Drugs Market by Disease Type (Revenue, Million, 2014 – 2025)

  • Blood Cancer
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Liver Cancer
  • Lung Cancer
  • Kidney Cancer

 

 Cancer Drugs Market by Treatment Categories (Revenue, Million, 2014 – 2025)

  • Chemotherapy
    • Alkylating Agents
    • Antimetabolites
  • Targeted Therapy
    • Monoclonal Antibodies
    • Tyrosine Kinase Inhibitors
  • Immunotherapy
  • Hormonal

 

Cancer Drugs Market by Distribution Channel (Revenue, Million, 2014 – 2025)

  • Hospitals
  • Drug Store
  • Specialty Pharmacy
  • E-Pharmacy

 

 Cancer Drugs Market Regional Outlook (Revenue, USD Million, 2014- 2025)

 

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

 

Cancer Market, Cancer Market Analytics, Cancer Market Share, Cancer Market Research, Cancer Market Forecast, Cancer Market Insight, Cancer Market Trend, Cancer Market Value,Cancer Market Size, Cancer Market Analysis, Cancer Market Survey, Blood Cancer Drugs Market, Oncology Drugs Market Analytics, Oncology Drugs Market Share, Oncology Drugs Market Research, Oncology Drugs Market Forecast, Oncology Drugs Market Insight, Oncology Drugs Market Trend, Oncology Drugs Market Value,Oncology Drugs Market Size, Oncology Drugs Market Analysis, Oncology Drugs Market Survey

Chapter 1 Methodology and Scope

  • Research Methodology
  • Research Scope & Assumptions
  • List of Data Sources

Chapter 2 Executive Summary

Chapter 3 Cancer Drugs Market Overview

  • Global Disease Landscape
  • Global Healthcare Expenditure

Chapter 4 Cancer Drugs Industry Outlook

  • Market Overview
  • Market Segmentation
  • Market Size and Growth Prospects
  • Leading Brand Dynamics
  • Key Market Drivers
    • Increasing patient base
    • Investment by Large Pharma for cancer research
    • Robust product pipeline
    • Increasing Collaboration
    • Increased diagnosis and early detection
    • Technological Advancements and newer drug approval
  • Key Market Challenges
    • Access barrier to high-cost drugs
    • Serious side effect to Cancer Drugs
    • Lack of Awareness and reimbursement plans in Emerging Countries
  • Key Opportunities Prioritized
  • Industry Analysis - Porter’s
  • Cancer Drugs Market-PESTEL Analysis

Chapter 5: - Cancer Drugs Market by “Disease Type” (USD Million)

  • Cancer Drugs Market Landscape by Disease Type- 2017 & 2025
    • Blood Cancer
  • Market Landscape Analysis, 2017-2025
    • Breast Cancer
  • Market Landscape Analysis, 2017-2025
    • Prostate Cancer
  • Market Landscape Analysis, 2017-2025
    • Colorectal Cancer
  • Market Landscape Analysis, 2017-2025
    • Cervical Cancer
  • Market Landscape Analysis, 2017-2025
    • Liver Cancer
  • Market Landscape Analysis, 2017-2025
    • Lung Cancer
  • Market Landscape Analysis, 2017-2025
    • Kidney Cancer
  • Market Landscape Analysis, 2017-2025
 

Chapter 6: - Cancer Drugs Market by “Treatment Categories” (USD Million)

Cancer Drugs Market Landscape by Treatment Categories- 2017 & 2025
  • Chemotherapy
    • Market Landscape Analysis, 2017-2025
  • Targeted therapy
    • Market Landscape Analysis, 2017-2025
  • Immunotherapy
    • Market Landscape Analysis, 2017-2025
  • Hormonal
    • Market Landscape Analysis, 2017-2025

Chapter 8: - Cancer Drugs Market by “Distribution Channel” (USD Million)

Cancer Drugs Market Landscape by Distribution Channel- 2017 & 2025
  • Hospitals
    • Market Landscape Analysis, 2017-2025
  • Drug Store
    • Market Landscape Analysis, 2017-2025
  • Specialty Pharmacy
    • Market Landscape Analysis, 2017-2025
  • E-Pharmacy
    • Market Landscape Analysis, 2017-2025

Chapter 9: Regional Market Outlook

Cancer Drugs Market Landscape by Region- 2017
  • North America Market Landscape Analysis, 2017-2025 (USD Mn)
    • U.S. Market Landscape Analysis, 2017-2025
    • Canada Market Landscape Analysis-2017-2025
  • Europe Market Landscape Analysis, 2017-2025 (USD Mn)
    • UK Market Landscape Analysis, 2017-2025
    • Germany Market Landscape Analysis, 2017-2025
    • France Market Landscape Analysis, 2017-2025
    • Italy Market Landscape Analysis, 2017-2025
    • Spain Market Landscape Analysis, 2017-2025
  • Latin America Market Landscape Analysis, 2017-2025 (USD Mn)
    • Brazil Market Landscape Analysis, 2017-2025
    • Mexico Market Landscape Analysis, 2017-2025
    • Colombia Market Landscape Analysis, 2017-2025
  • Asia Pacific Market Landscape Analysis, 2017-2025 (USD Mn)
    • Japan Market Landscape Analysis, 2017-2025
    • China Market Landscape Analysis, 2017-2025
    • India Market Landscape Analysis, 2017-2025
  • Middle East & Africa Market Landscape Analysis, 2014-2025 (USD Mn)
    • Saudi Arabia Market Landscape Analysis, 2014-2025
    • South Africa Market Landscape Analysis, 2014-2025
Chapter 10: Pricing Analysis   Optimal Price Points (OPP), Indifference price points (IPP) and Range of Acceptable Prices and (RAP) of leading brands by Region- 2017
  • North America Pricing Analysis (OPP, IPP, and RAP - 2017)
    • U.S. Pricing Analysis-2017
    • Canada Pricing Analysis-2017
  • Europe Pricing Analysis (OPP, IPP, and RAP - 2017)
    • UK Pricing Analysis-2017
    • Germany Pricing Analysis-2017
    • France Pricing Analysis-2017
    • Italy Pricing Analysis-2017
    • Spain Pricing Analysis-2017
  • Latin America Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Brazil Pricing Analysis-2017
    • Mexico Pricing Analysis-2017
    • Colombia Pricing Analysis-2017
  • Asia Pacific Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Japan Pricing Analysis-2017
    • China Pricing Analysis-2017
    • India Pricing Analysis-2017
  • Middle East Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Saudi Arabia Pricing Analysis-2017
    • South Africa Pricing Analysis-2017

Chapter 11: Cancer Drugs Pipeline Analysis

  • Executive Summary
  • Late Stage Pipeline analysis
  • Key R&D trends

Chapter 12: Cancer Drugs Merger & Acquisition Outlook

  • Factors driving M&A in Cancer Drugs market
  • Key trends and future outlook

Chapter 13: Competitive Landscape

  • AstraZeneca
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Bristol Myers Squibb
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Hoffmann-La Roche Ltd
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Eli Lilly
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Bayer AG
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • GlaxoSmithKline
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Boehringer Ingelheim
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Takeda Pharmaceutical
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Merck & Co
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Janssen Pharmaceuticals
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Genentech Inc.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
    List of Tables  
  • TABLE 1 Cancer Drugs Market - Industry Snapshot & Key Buying Criteria, 2014 - 2025
  • TABLE 2 Global Cancer Drugs Market, 2014 – 2025
  • TABLE 3 Global Cancer Drugs Market Analysis by Product-2017
  • TABLE 4 Global Cancer Drugs Market Analysis by Technology -2017
  • TABLE 5 Global Cancer Drugs Market Analysis by Application-2017
  • TABLE 7 Global Cancer Drugs Market Analysis by Geography-2017
  • TABLE 8 Global Cancer Drugs Market Analysis by Leading Brands-2017
  • TABLE 9 Cancer Drugs Market - Key market driver analysis
  • TABLE 10 Cancer Drugs Market - Key market restraint analysis
  • TABLE 11 North America Market Cancer Drugs Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 12U.S. Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 13 Canada Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 14 Europe Cancer Drugs Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 15 U.K Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 16 Germany Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 17 France Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 18 Italy Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 19 Spain Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 20 Latin America Cancer Drugs Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 21 Brazil Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 22 Mexico Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 20 Colombia Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 21 Asia Pacific Cancer Drugs Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 22 Japan Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 23 China Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 24 India Cancer Drugs Market Landscape Analysis, 2017-2025
  • TABLE 25 North America Pricing Analysis
  • TABLE 26 North America Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 27 U.S. Pricing Analysis-2017
  • TABLE 28 Canada Pricing Analysis-2017
  • TABLE 29 Europe Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 30 U.K Pricing Analysis-2017
  • TABLE 31 Germany Pricing Analysis-2017
  • TABLE 32 France Pricing Analysis-2017
  • TABLE 33 Italy Pricing Analysis-2017
  • TABLE 34 Spain Pricing Analysis-2017
  • TABLE 35 Latin America Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 36 Brazil Pricing Analysis-2017
  • TABLE 37 Mexico Pricing Analysis-2017
  • TABLE 38 Colombia Pricing Analysis-2017
  • TABLE 39 Asia Pacific Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 40 Japan Pricing Analysis-2017
  • TABLE 41 China Pricing Analysis-2017
  • TABLE 42 India Pricing Analysis-2017
  • TABLE 43 Middle East Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 44 Saudi Arabia Pricing Analysis-2017
  • TABLE 45 South Africa Pricing Analysis-2017
  List of Figures  
  • 1 Cancer Drugs Market Segmentation
  • 2 Market Size & Growth Prospects
  • 3 Leading Brand Dynamics
  • 4 Penetration & Growth Prospects
  • 5 Industry Analysis – Porter’s
  • 6 Cancer Drugs Market – PESTEL Analysis
  • 7 Cancer Drugs Market Share by Product Type, 2017 & 2025
  • 7 Cancer Drugs Market Share by Cell Type, 2017 & 2025
  • 7 Cancer Drugs Market Share by Technique, 2017 & 2025
  • 7 Cancer Drugs Market Share by Application, 2017 & 2025
  • 7 Cancer Drugs Market Share by End-Use, 2017 & 2025
  • 10 Cancer Drugs Market Share by Region, 2017 & 2025

Key Insights Addressed:  

  • Defining market size from 2014 to 2017.
  • Estimating market growth till 2025 and consequence market forecast.
  • Identifying market drivers, restraints & future opportunities and allowing decision-maker with a range of possible outcomes and the probabilities that will occur for any choice of action.
  • Market segments and regions that will drive or lead market growth.
  • Defining Optimal Price Point (OPP) which will be accepted and recommended by maximum customers.
  • A bird’s-eye view of competitive landscape and the key market players.
  • Key strategic growth driver adopted by market players. In-depth analysis of their strategies and implication on competition & growth.
    Key Findings:  
  • The global cancer drugs market was valued at $87.6 Billion in 2017 and is forecast to grow at a modest xx.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $135.5 Billion.
  • As per WHO, 8.8 million people worldwide died from cancer in 2015. The most common causes of cancer death are cancers of Lung (1.69 million deaths), Liver (788 000 deaths), Colorectal (774 000 deaths), Stomach (754 000 deaths), Breast (571 000 deaths).
  • We have segmented the Cancer Drugs market into Blood Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Kidney Cancer.
  • The key market participants include AstraZeneca, Bristol Myers Squibb, Bayer AG, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Takeda Pharmaceutical, Merck & Co., Genentech Inc., Boehringer Ingelheim, and F. Hoffman-La Roche Ltd.

Ameri Research implies a unique methodology of published information and primary research to bring key insights to customer decision making process. Our analytics model helps us to understand the structured and unstructured information from various sources. Key steps involves in the process are as below-

    1. Analyzing Published Information- Access to large pool of paid and unpaid published information via different sources and analyzing market trend.
    2. Setting Foundation- Input from analysis of secondary sources set our foundation to market analysis and helps in setting the scope for further research. Setting the scope involves Ameri Research proprietary statistical model, discussion with industry leaders, internal brainstorming, key discussion pointers from various forums etc.
    3. Need Gap Analysis- Defining the gap between our scope and availability of information.
    4. KOL Panel Discussion- Focused Group Discussion with a structured discussion guide to fine tune the gap and deriving the factors driving/restraining the market trend.
    5. Quantitative Research- Sampling large number of industry players, Education/Research Institutes, Government bodies, NGOs, Individual acclaimed researchers and conducting the primary interview with a structured questionnaire.
    6. Data Triangulation- We apply bottom-up demand approach or top-down estimation or a combined approach to triangulate the data points.
    7. Analyst Comment- Each of our analysts carries large pool of experience from domain perspective and add their value which is directional in nature
global-aesthetic-dermatology-market

To request a free sample copy of this report, please complete the form below verified and secure

We offer complete free customization that addresses client’s need. This includes insights from primary market research and a 60-minute free analyst consultation post report purchase.

This website is secure and your personal details are safe. Privacy policy

Description

The global cancer drugs market was valued at $87.6 Billion in 2017 and is forecast to grow at a modest xx.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $135.5 Billion.

 

As per WHO, 8.8 million people worldwide died from cancer in 2015. The most common causes of cancer death are cancers of Lung (1.69 million deaths), Liver (788 000 deaths), Colorectal (774 000 deaths), Stomach (754 000 deaths), Breast (571 000 deaths). Nearly 1 out of every 6 deaths globally. 30-50% of cancer cases can be prevented. It’s causing an annual economic cost of USD 1.16 trillion globally. Cancer-causing infections, such as hepatitis and human papillomavirus (HPV), are responsible for up to 25% of cancer cases in low- and middle-income countries.

 

Cancer arises from the transformation of normal cells into tumor cells in a multistage process that generally progresses from a pre-cancerous lesion to a malignant tumor. This can result in individuals’ genetic factors along with physical carcinogens, chemical carcinogens, and biological carcinogens.

 

Global Cancer Drugs Market Outlook To 2025

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Cancer Drugs”

 

Estimated Average product/ service cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the U.S., the cancer drugs are available at USD xxx- USD xxxx. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.

 

 

 Cancer Drugs Market by “Disease Type”

 

We have segmented the Cancer Drugs market into Blood Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Kidney Cancer.  Lung Cancer is the major cause of death due to cancer followed by Liver and Breast Cancer. We are estimating breast cancer to grow at a CAGR of 25.8% during the forecast period. With an aging population and change in lifestyle, the incidence of cancer is rising steadily.

 

 Cancer Drugs Market by “Treatment Categories”

 

We have segmented the Cancer Drugs market by treatment into Chemotherapy ((Alkylating Agents, and Antimetabolites), Targeted Therapy (Monoclonal Antibodies and Tyrosine Kinase Inhibitors), Immunotherapy and Hormonal. We are observing newer biologic into immunotherapy shaping the Cancer Drugs. Advancing novel therapeutic agents for the treatment of malignancy proving costly and lengthy process. Cost estimates for de novo drug discovery range from $500 million to $2 billion.

 

 Cancer Drugs Market by “Distribution Channel”

 

We have segmented the cancer drugs market based on distribution channel as Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy. Majority of products channelized through hospitals (Particularly Chemo, Surgery and Radiation). However, we are observing the increased role of specialized pharmacy and E-pharmacy in the distribution/ dispensation of treatment drugs. Patient education to increase compliance and Persistency plays a key role in the outcome. Many payors are linking reimbursement to the outcome.

 

 

Regional Segmentation

 

North America accounted for the maximum revenue share of over 70% in 2017 due to increased patient number, lifestyle followed by availability of treatment options, better reimbursement plan, and RND.  Followed by EU- Top 5 countries contribute $X.6 Billion in 2017 and expected to reach $x.5 Billion by 2023.

With changing lifestyle in developing countries and availability of treatment option, we are observing a rise in patient numbers in developing countries. However, these markets represent a minuscule percentage of the overall market.

 

“Competitive Landscape” and “Merger & Acquisition Insights”

 

The key market participants include AstraZeneca, Bristol Myers Squibb, Bayer AG, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Takeda Pharmaceutical, Merck & Co., Genentech Inc., Boehringer Ingelheim, and F. Hoffman-La Roche Ltd. The growing investment in research and development is driving the companies to innovate, stay market relevant and retain their share. Moreover, there are several startup companies working on stem cell and biologic research, and these companies are considered as strategic assets for merger and acquisition. Non-platinum based PARP inhibitors and VEGF inhibitors are changing the treatment paradigm for cancer significantly. We are observing a new drug development for cancer ONX-0801 is in Phase1. Some of the most notable transactions in the recent past include,

  • Novogen Limited, an oncology-focused biotechnology company, becomes Kazia Therapeutics Limited.
  • Tesaro’s acquisition with prospective bidder has diminished in event of news that rival drugs from AstraZeneca and Clovis are just as effective as Tesaro’s niraparib.

 

Market Segmentation

 

 Cancer Drugs Market by Disease Type (Revenue, Million, 2014 – 2025)

  • Blood Cancer
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Liver Cancer
  • Lung Cancer
  • Kidney Cancer

 

 Cancer Drugs Market by Treatment Categories (Revenue, Million, 2014 – 2025)

  • Chemotherapy
    • Alkylating Agents
    • Antimetabolites
  • Targeted Therapy
    • Monoclonal Antibodies
    • Tyrosine Kinase Inhibitors
  • Immunotherapy
  • Hormonal

 

Cancer Drugs Market by Distribution Channel (Revenue, Million, 2014 – 2025)

  • Hospitals
  • Drug Store
  • Specialty Pharmacy
  • E-Pharmacy

 

 Cancer Drugs Market Regional Outlook (Revenue, USD Million, 2014- 2025)

 

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

 

Cancer Market, Cancer Market Analytics, Cancer Market Share, Cancer Market Research, Cancer Market Forecast, Cancer Market Insight, Cancer Market Trend, Cancer Market Value,Cancer Market Size, Cancer Market Analysis, Cancer Market Survey, Blood Cancer Drugs Market, Oncology Drugs Market Analytics, Oncology Drugs Market Share, Oncology Drugs Market Research, Oncology Drugs Market Forecast, Oncology Drugs Market Insight, Oncology Drugs Market Trend, Oncology Drugs Market Value,Oncology Drugs Market Size, Oncology Drugs Market Analysis, Oncology Drugs Market Survey

Additional information

Price

Single User $5,650, Multiple User $8,650, Enterprise User $12,650